Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Welcome to Pharm-Olam Insights

Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.

Understanding-COVID-19_pagePreview
Multicenter Phase III Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP)

Pharm-Olam was hired to support a Phase 3 study of a monoclonal antibody (mAb) and its impact on patients with...


(0 minute read)

Tags: Infectious Disease & Vaccines

Ethically Consenting Patients in Ventilator-Associated Studies

Pharm-Olam is experienced in dealing with ventilator-associated studies and consenting patients in an Intensive Care Unit...


(7 minute read)

Tags: Infectious Disease & Vaccines, COVID-19

Lessons Learned From a Phase II Influenza Clinical Trial

In this post, we discuss elements and lessons learned from a recent BARDA funded Influenza A Phase II study.  The study’s...


(3 minute read)

Tags: Pharm-Olam Insights, Infectious Disease & Vaccines

Completing a Rescue Study Transition - How Much Time Do You Need?

Clinical Trials are large complex projects, and occasionally a sponsor may need to make a change to bring an underperforming...


(5 minute read)

Tags: Pharm-Olam Insights, "Rescue CRO"

Importance of Natural History Studies to Rare Disease Drug Development

When working on a rare disease program, there are far reaching benefits to conducting a natural history (NH) study. In this...


(0 minute read)

Tags: Rare & Orphan Disease

Join other Clinical Development experts to receive the latest industry news, trends and insights.

Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.

GDPR_Checklist-cover